reports
Information relating to the stabilization activities carried out in th...
Information relating to the stabilization activities carried out in the context of its recent offering Daix (France), New York City (New York, United States), November 24, 2025 – Publication of information relating to the stabilization activities carried out in the context of the recent public offering of Inventiva (the "Company" or "Inventiva") in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01. As announced on 18 November 2025, the underwriters have exercised in full the...
Informations relatives aux activités de stabilisation menées dans le c...
Informations relatives aux activités de stabilisation menées dans le cadre de sa récente offre au public Daix (France), New York City (New York, États-Unis), le 24 novembre 2025 - Publication d'informations relatives aux activités de stabilisation menées dans le cadre de la récente offre au public d'Inventiva (la "Société" ou "Inventiva") aux États-Unis (l'"Offre") de 38.961.038 American Depositary Shares ("ADSs"), chacune représentant une action ordinaire de la Société, d'une valeur nominale de 0,01 euro. Comme annoncé le 18 novembre 2025, les teneurs de livre associés ont intégralement ex...
- ING Helpdesk
Benelux Morning Notes
Colruyt: Only 5 stores left to divest in France. EVS: Lower end of the range becomes the base case, on longer lead times. Fagron: Two EMEA acquisitions and California license for FSS. Kinepolis: “Wicked” achieves solid box office. OCI: Divesting Rotterdam ammonia terminal for €290m. Prosus: 1HFY26 results – on track
- Jacob Mekhael
Inventiva 9M25 results show all is on track
Inventiva reported 9M25 results which hold no surprises, and confirmed its recently updated cash runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to end of 1Q27 (previously end of 3Q26). This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We update our model for the additional cash and shares (185m outstanding), as well as tweak some of our o...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thibault Leneeuw
- Wim Lewi
Fagron strengthens EMEA leadership with acquisitions in Poland and Hun...
Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 November 2025 – 7:00 AM CET Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Fagron, the global leader in pharmaceutical compounding, has reinforced its EMEA position with the acquisitions of a book of business from Amara (Poland) and Magilab (Hungary). These deals support F...
Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen e...
Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen en Hongarije en kondigt belangrijke ontwikkelingen aan voor de Noord-Amerikaanse activiteiten Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 24 November 2025 – 07.00 uur CET Fagron versterkt leiderschap in de EMEA-regio met overnames in Polen en Hongarije en kondigt belangrijke ontwikkelingen aan voor de Noord-Amerikaanse activiteiten Fagron, wereldwijd marktleider in farmaceutische bereidingen, heeft zijn positie in de EMEA-regio versterkt door de overname van een klantenportefeuille va...
Inventiva reports 2025 Third Quarter Financial Information¹
Inventiva reports 2025 Third Quarter Financial Information¹ Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapi...
Inventiva publie ses informations financières du 3ème trimestre 2025¹
Inventiva publie ses informations financières du 3ème trimestre 2025¹ Trésorerie et équivalents de trésorerie à 97,6 millions d’euros, et 24,7 millions d’euros en dépôts à court terme2 au 30 septembre.Chiffre d’affaires de 4,5 millions d’euros sur les neuf premiers mois de 2025.Horizon de trésorerie prévue jusqu’à la fin du premier trimestre 20273, incluant le produit net de l'offre au public réalisée en novembre 2025 Daix (France), New York City (New York, Etats-Unis), le 21 novembre 2024 – Inventiva (Euronext Paris and Nasdaq :IVA) (la « Société »), société biopharmaceutique spécialisée ...
Inventiva announces full exercise of Underwriters’ Option, bringing pr...
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the underwriters of the previously announced public offering in the United States (the "Offering") of 38,961,038 American Depositary Shares ("A...
Inventiva annonce l’exercice intégral de l’Option des Banques portant ...
Inventiva annonce l’exercice intégral de l’Option des Banques portant le montant de l'Offre à environ 172,5 millions de dollars Daix (France), New York City (New York, États-Unis), le 17 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui que les teneurs de livre associés de l'offre au public aux Etats-Unis préalablement annoncée (l’« Offre ») de 38.961.0...
Fagron completes share buy-back program
Fagron completes share buy-back program Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44,000 of its owns shares at an average price of €20.7208 per share corresponding to a total amount of €911,717.00. A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,093.00. The share buy-back program was announced on ...
Voortgang aandeleninkoopprogramma Fagron
Voortgang aandeleninkoopprogramma Fagron Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 14 november 2025 – 18u CET Voortgang aandeleninkoopprogramma Fagron In de periode van 10 november 2025 tot en met 14 november 2025 heeft Fagron 44.000 eigen aandelen ingekocht voor een gemiddelde prijs van € 20,7208 per aandeel wat overeenkomt met een totaalbedrag van € 911.717,00. Het totaal van 200.000 Fagron aandelen is aangekocht tegen een gemiddelde koers van € 20,6805 per aandeel, wat overeenkomt met een totaalbedrag van € 4.136.093,00. Het aandeleninkoopprogramma was aan...
- Mathijs Geerts Danau
Inventiva Raises $ 150m gross proceeds in a public offering
Inventiva announced the issuance of ~39m new ADSs in a public offering in the US at an issue price of $ 3.85 per ADS (approx. 0.9% discount to the VWAP of Euronext trading the previous day) resulting in gross proceeds of $ ~150m and net proceeds of € ~121m. Inventiva's cash runway is extended to at least 1Q27 (previously 3Q26), assuming no Tranche 3 warrants will be issued. We plan to incorporate the new share capital and cash in our target price in the future. We view this raise as a positive a...
- Hilde Van Boxstael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Lewi
Inventiva announces trading resumption of its ordinary shares on Euron...
Inventiva announces trading resumption of its ordinary shares on Euronext Paris Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 4:30 p.m. (CET). Trading of the ordinary shares of the Company was halted, at the Comp...
Inventiva annonce la reprise des négociations de ses actions ordinaire...
Inventiva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé la reprise des négociations de ses actions ordinaires sur le marché réglementé de Euronext à Paris aujourd’hui à compter de 16h30 (CET). La négociation des actions ...
Inventiva announces pricing of upsized public offering of approximatel...
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the pricing of its previously announced underwritten public offering, in the United States only, of 38,961,038 new American Depositary Shares ("ADSs"), ea...
Inventiva annonce les modalités définitives ainsi que l'extension de l...
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au public d'American Depositary Shares d'approximativement 150 millions de dollars Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui la fixation des modalités définitives de l'offre au public préalablement annoncée, au...
- Mathijs Geerts Danau
Inventiva Launches capital increase for gross proceeds of € 108m
Inventiva announced the launch of a capital increase by way of underwritten public offering of ADSs in the US. The company intends to raise € 108m and will use the proceeds to fund the continuation of the phase 3 trial, and prepare for commercialization and an outcomes trial. We view this raise as a positive and reiterate our BUY rating and € 8 TP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.